Immix Biopharma, Inc. (IMMX)
9.45
+0.16
(+1.72%)
USD |
NASDAQ |
Oct 09, 15:20
Immix Biopharma EPS Diluted (Quarterly) : -0.1812 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.1812 |
| March 31, 2026 | -0.1822 |
| December 31, 2025 | -0.2792 |
| September 30, 2025 | -0.2376 |
| June 30, 2025 | -0.2209 |
| March 31, 2025 | -0.1529 |
| December 31, 2024 | -0.1747 |
| September 30, 2024 | -0.243 |
| June 30, 2024 | -0.1526 |
| March 31, 2024 | -0.2244 |
| December 31, 2023 | -0.2555 |
| Date | Value |
|---|---|
| September 30, 2023 | -0.2304 |
| June 30, 2023 | -0.2378 |
| March 31, 2023 | -0.1784 |
| December 31, 2022 | -0.2872 |
| September 30, 2022 | -0.1102 |
| June 30, 2022 | -0.1126 |
| March 31, 2022 | -0.0963 |
| December 31, 2021 | -1.720 |
| September 30, 2021 | -0.0519 |
| March 31, 2021 | -0.3012 |
| September 30, 2020 | -0.015 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Atossa Therapeutics, Inc. | -0.9531 |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Savara, Inc. | -0.1587 |
| Vericel Corp. | 0.0422 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -11.56M |
| Total Expenses (Quarterly) | 11.56M |
| Enterprise Value | 433.46M |
| Earnings Yield | -9.31% |
| Normalized Earnings Yield | -9.314 |